. "Appendix D-1: The Prospects for Immunizing Against Dengue Virus." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries
Halstead, S.B. 1983. Selective primary health care: Strategies for control of disease in the developing world. XI. Dengue. Rev. Infect. Dis. 6(2):251–264.
Halstead, S.B. 1985. Personal communication, The Rockefeller Foundation, New York, New York.
Halstead, S.B., and N.E.Palumbo. 1973. Studies on the immunization of monkeys against dengue. II. Protection following inoculation of combinations of viruses. Am. J. Trop. Med. Hyg. 22(3):375–381.
Halstead, S.B., A.R.Diwan, N.J.Marchette, N.E.Palumbo, and L. Srisukonth. 1984a. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. I. Attributes of uncloned virus at different passage levels. Am. J. Trop. Med. Hyg. 33(4):654–665.
Halstead, S.B., N.J.Marchette, A.R.Diwan, N.E.Palumbo, and R. Putvatana. 1984b. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. II. Attributes of virus cloned at different dog kidney passage levels. Am. J. Trop. Med. Hyg. 33(4):666–671.
Halstead, S.B., N.J.Marchette, A.R.Diwan, N.E.Palumbo, R.Putvatana, and L.K.Larsen. 1984c. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. III. Reversion to virulence by passage of cloned virus in fetal rhesus lung cells. Am. J. Trop. Med. Hyg. 33(4):672–678.
Halstead, S.B., K.H.Eckels, R.Putvatana, L.K.Larsen, and N.J. Marchette. 1984d. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. IV. Characterization of a vaccine candidate in fetal rhesus lung cells. Am. J. Trop. Med. Hyg. 33(4):679–683.
Hotta, S. 1957. Some immunological properties of dengue virus cultivated in tissue culture. Ann. Trop. Med. Parasitol. 51:249–255.
National Institute of Allergy and Infectious Diseases. 1985. Program for Accelerated Development of New Vaccines. Progress Report. Bethesda, Md.: National Institutes of Health.
Sabin, A.B., and R.W.Schlesinger. 1945. Production of immunity to dengue with virus modified by propagation in mice. Science 101:640–642.
Sangkawibha, N., S.Rojanasuphot, S.Ahandrik, S.Viriyapongse, S. Jatanasen, V.Salitul, B.Phanthumachinda, and S.B.Halstead. 1984. Risk factors in dengue shock syndrome: A prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am. J. Epidemiol. 120(5):653–669.
Schlesinger, R.W., I.Gordon, J.W.Frankel, J.N.Winter, P.R.Patterson, and W.R.Dorrance. 1956. Clinical and serological response of man to immunization with attenuated dengue and yellow fever viruses. J. Immunol. 77:352–364.
Schlesinger, J.J., Brandriss, M.W., and E.E.Walsh. 1985. Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the non-structural glycoproteins gp 48 and by active immunization with gp 48. J. Immunol. 135:2805–2809.
Wisseman, C.L., Jr., B.H.Sweet, and E.C.Rosenzweig. 1963. Attenuated living type 1 dengue vaccines. Am. J. Trop. Med. Hyg. 12:620–623.